Literature DB >> 25514889

Advances in pediatric cancer therapy: potential applicability in Indian scenario.

Sameer Bakhshi1, Bivas Biswas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25514889     DOI： 10.1007/s12098-014-1653-7

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  10 in total

1.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  FLT3-ITD mutation in relation to FLT3 expression in pediatric AML: a prospective study from India.

Authors:  Surender Kumar Sharawat; Radhika Bakhshi; Sreenivas Vishnubhatla; Ritu Gupta; Sameer Bakhshi
Journal:  Pediatr Hematol Oncol       Date:  2014-02-05       Impact factor: 1.969

3.  Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Authors:  Yoav H Messinger; Paul S Gaynon; Richard Sposto; Jeannette van der Giessen; Elena Eckroth; Jemily Malvar; Bruce C Bostrom
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

4.  FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).

Authors:  Patricia Anne Dinndorf; Joseph Gootenberg; Martin H Cohen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2007-08

5.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Richard B Womer; Daniel C West; Mark D Krailo; Paul S Dickman; Bruce R Pawel; Holcombe E Grier; Karen Marcus; Scott Sailer; John H Healey; John P Dormans; Aaron R Weiss
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

6.  Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.

Authors:  Stephan Metzelder; Ying Wang; Ellen Wollmer; Michael Wanzel; Sabine Teichler; Anuhar Chaturvedi; Martin Eilers; Erich Enghofer; Andreas Neubauer; Andreas Burchert
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

7.  Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.

Authors:  M J Borowitz; D J Pullen; J J Shuster; D Viswanatha; K Montgomery; C L Willman; B Camitta
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

8.  Umbilical cord blood transplant for malignancies: a hope or hype.

Authors:  Ankur Bahl; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2013-05-10       Impact factor: 1.967

9.  6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Smita Bhatia; Wendy Landier; Lindsey Hageman; Heeyoung Kim; Yanjun Chen; Kristine R Crews; William E Evans; Bruce Bostrom; Jacqueline Casillas; David S Dickens; Kelly W Maloney; Joseph P Neglia; Yaddanapudi Ravindranath; A Kim Ritchey; F Lennie Wong; Mary V Relling
Journal:  Blood       Date:  2014-05-14       Impact factor: 22.113

10.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors:  Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.